DRD2 and neuroendocrine neoplasm: A phase II clinical trial of ONC201, a DRD2 antagonist, in human patients with metastatic neuroendocrine tumors including PPGL showed clinical benefit in the majority of patients with PPGL (5 partial responses, 7 stable diseases, 2 progressive diseases) (27).